These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28006087)

  • 1. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
    Thorpe LM; Schrock AB; Erlich RL; Miller VA; Knost J; Le-Lindqwister N; Jujjavarapu S; Ali SM; Liu JJ
    Head Neck; 2017 Mar; 39(3):E40-E44. PubMed ID: 28006087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
    Sharon E; Kelly RJ; Szabo E
    Head Neck Oncol; 2010 May; 2():12. PubMed ID: 20504363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
    Park JC; Ma TM; Rooper L; Hembrough T; Foss RD; Schmitt NC; Sawhney R; Flanders A; Kang H
    Head Neck; 2018 Dec; 40(12):E100-E106. PubMed ID: 30478962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
    Kurzrock R; Bowles DW; Kang H; Meric-Bernstam F; Hainsworth J; Spigel DR; Bose R; Burris H; Sweeney CJ; Beattie MS; Blotner S; Schulze K; Cuchelkar V; Swanton C
    Ann Oncol; 2020 Mar; 31(3):412-421. PubMed ID: 32067683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual gain of HER2 and EGFR gene copy numbers impacts the prognosis of carcinoma ex pleomorphic adenoma.
    Nishijima T; Yamamoto H; Nakano T; Nakashima T; Taguchi K; Masuda M; Motoshita J; Komune S; Oda Y
    Hum Pathol; 2015 Nov; 46(11):1730-43. PubMed ID: 26345124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
    Lee J; Park S; Jung HA; Lee SH; Seo S; Kim SB; Kim JW; Lee KW; Kang EJ; Kim JW; Choi YJ; Shim BY; An HJ; Park LC; Shin SH; Kim JJ; Oh SY; Kim MK; Ahn MJ
    Cancer; 2023 Oct; 129(19):2966-2974. PubMed ID: 37246414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients.
    De Block K; Vander Poorten V; Dormaar T; Nuyts S; Hauben E; Floris G; Deroose CM; Schöffski P; Clement PM
    Acta Clin Belg; 2016 Dec; 71(6):383-388. PubMed ID: 27285571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
    Falchook GS; Lippman SM; Bastida CC; Kurzrock R
    Head Neck; 2014 Mar; 36(3):E25-7. PubMed ID: 23852769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study.
    Dori S; Vered M; David R; Buchner A
    J Oral Pathol Med; 2002 Sep; 31(8):463-7. PubMed ID: 12220353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.
    Wang K; Russell JS; McDermott JD; Elvin JA; Khaira D; Johnson A; Jennings TA; Ali SM; Murray M; Marshall C; Oldham DS; Washburn D; Wong SJ; Chmielecki J; Yelensky R; Lipson D; Miller VA; Stephens PJ; Serracino HS; Ross JS; Bowles DW
    Clin Cancer Res; 2016 Dec; 22(24):6061-6068. PubMed ID: 27334835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review.
    Kaidar-Person O; Billan S; Kuten A
    Med Oncol; 2012 Jun; 29(2):704-6. PubMed ID: 21380780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
    Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
    Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.
    Gilbert MR; Sharma A; Schmitt NC; Johnson JT; Ferris RL; Duvvuri U; Kim S
    JAMA Otolaryngol Head Neck Surg; 2016 May; 142(5):489-95. PubMed ID: 26939990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained response of HER2-positive metastatic salivary adenocarcinoma, not otherwise specified, treated with trastuzumab.
    Ghazali N; Parker L; Settle K; Lubek JE
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Sep; 122(3):292-9. PubMed ID: 27289263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu gene amplification in carcinoma ex pleomorphic adenoma in relation to progression and prognosis: a chromogenic in-situ hybridization study.
    Hashimoto K; Yamamoto H; Shiratsuchi H; Nakashima T; Tamiya S; Nishiyama K; Higaki Y; Komune S; Tsuneyoshi M; Oda Y
    Histopathology; 2012 May; 60(6B):E131-42. PubMed ID: 22486195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: ado-trastuzumab as second-line treatment in HER2 positive salivary duct carcinoma.
    Taha T; Billan S
    Anticancer Drugs; 2022 Jan; 33(1):e760-e763. PubMed ID: 34387606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.
    Haderlein M; Scherl C; Semrau S; Lettmaier S; Hecht M; Erber R; Iro H; Fietkau R; Agaimy A
    Strahlenther Onkol; 2017 Nov; 193(11):961-970. PubMed ID: 28828496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas.
    Clauditz TS; Reiff M; Gravert L; Gnoss A; Tsourlakis MC; Münscher A; Sauter G; Bokemeyer C; Knecht R; Wilczak W
    Pathology; 2011 Aug; 43(5):459-64. PubMed ID: 21670724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab for the treatment of salivary duct carcinoma.
    Limaye SA; Posner MR; Krane JF; Fonfria M; Lorch JH; Dillon DA; Shreenivas AV; Tishler RB; Haddad RI
    Oncologist; 2013; 18(3):294-300. PubMed ID: 23429737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-erbB-2 oncoprotein expression and amplification in pleomorphic adenoma and carcinoma ex pleomorphic adenoma: relationship to prognosis.
    Müller S; Vigneswaran N; Gansler T; Gramlich T; DeRose PB; Cohen C
    Mod Pathol; 1994 Aug; 7(6):628-32. PubMed ID: 7991521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.